Synthesis, antitubercular evaluation and molecular docking studies of phthalimide bearing 1,2,3-triazoles

In a search for safer and potent antitubercular agents, here a library of newly substituted dioxoisoindolinylmethyl-triazolyl-N-phenylacetamide derivatives (5a–l) has been synthesized via click chemistry approach. All synthesized compounds were evaluated for their antitubercular activity against Mycobacterium tuberculosis H37Rv (MTB). Among the screened compounds, 5d, 5e, 5h, and 5l showed good antitubercular activity. The compounds 5d and 5l have shown very effective antitubercular activity against Mycobacterium tuberculosis H37Rv (MTB) with MIC 12.5 μg/mL. All the newly synthesized compounds were thoroughly characterized by 1H NMR, 13C NMR, and HRMS spectral data. We further performed exploratory docking studies on the crystal structure of Mycobacterium tuberculosis enoyl reductase to demonstrate the mechanism of antitubercular activity.</p

Synthesis of New Amide Linked Biphenoloxy 1,2,3-Triazoles as Antitubercular and Antimicrobial Agents

New 1,2,3-triazoles bearing biphenoloxymethyl and acetanilido moieties (5a-5l) have been synthesized, starting from 4-phenylphenol (1) following click chemistry approach. The synthesized compounds have been thoroughly characterized by their 1H NMR, 13C NMR and HRMS spectral data. These compounds were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv and antimicrobial activity against pathogenic microbia. Among the screened compounds, 5a and 5i have displayed notable antitubercular activity with MIC 25 µg/mL. Compounds 5a, 5b, 5c, 5 g, 5i and 5 l have shown effective inhibition against most of tested pathogens. Molecular docking results of compounds 5a and 5i show the binding modes of the synthesized compounds into the active site of mycobacterial enoyl reductase. The synthesized compounds have also been analyzed for their ADME properties. By considering all these results, the present research work will offer a promising lead series for discovery of emerging potent antitubercular agents.</p